Derpixa by Scite Pharma, LLC DERPIXA-

Derpixa by

Drug Labeling and Warnings

Derpixa by is a Other medication manufactured, distributed, or labeled by Scite Pharma, LLC. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • Indication for use

    Derpixa is intended to be used under the direction of healthcare practitioners in the management of cutaneous reactions.

    Derpixa is indicated for use on all types of wounds, toxic and compromised skin including:

    • Cutaneous reactions
    • Pruritic, itchy skin
    • Xerotic, dry skin
    • Desquamation
    • Fissures of skin and nail folds
    • Blisters
    • Medical Adhesive-Related Skin Injuries (MARSI)
    • Erythema
    • Infusion reactions
    • Rashes, including: Maculopapular rash, hand-foot syndrome, GVHD, acneiform reaction, peri – and appendageal (hair follicles, sweat glands)

    Derpixa is indicated for the relief of dry, itching, flaking, peeling and irritated skin, as well as the symptomatic relief of pain, redness and heat sensation.

    Derpixa may be directly applied to dry skin, open wounds and compromised or desquamating skin surfaces, including cutaneous rashes.

    Derpixa gel is bacteriostatic and inert.

    It contains no alcohols, parabens or fragrances.

    Derpixa can be used with or without a secondary protective dressing.

    Derpixa is suitable for children and people with sensitive skin.

    Derpixa is intended for single patient use.

  • Directions for use

    Image

    On the first use of 1 oz (28.5 g) tubes remove the cap, then the protective seal and close with the cap after use.

    Ensure that the affected superficial area is clean and dry.

    Apply a very thin layer of Derpixa directly to the affected area and allow the gel to dry.

    When applied correctly to exposed areas, Derpixa should be dry in 5–6 minutes.

    If it takes longer to dry you have probably applied too much.

    Gently remove the excess with a clean tissue or gauze and allow the drying process to continue.

    Once dry, Derpixa may be covered by sunscreen, cosmetics and clothing.

    Derpixa should be applied at least twice daily to affected areas, as needed or as advised by your physician.

    For best results Derpixa should be maintained in continuous contact with the skin (24 hours a day/7 days a week).

    How much Derpixa do I need?

    Derpixa gel is an advanced formulation that requires substantially less product per application than typical creams or gels.

    Derpixa 1 oz (28.5 g) is enough to treat an area of 6 × 12 inch (15 × 30 cm) twice per day for 30 days.

  • Warning

    • For external use only.
    • Derpixa should not be placed in contact with the eyes.
    • Derpixa should not be applied over topical medications unless advised by your physician.
    • Derpixa may stain clothing if not completely dry. If staining occurs, dry cleaning should be able to remove it without damaging the fabric.
    • For correct storage please reclose the tube tightly with the cap.
    • If irritation occurs, discontinue use and consult your physician.
    • Keep out of the reach of children.
    • Do not use after the expiration (EXP) date printed on the tube. The expiration (EXP) date does not change once the tube has been opened.
    • Do not use if the tube is damaged.
  • Contraindications

    Do not administer to patients with known hypersensitivity to the ingredients of this product.

  • STERILE UNTIL OPENED

    Ingredients: Dimethylpolysiloxane, dihydroxysiloxane and alkylmethylsiloxane.

  • How supplied

    Derpixa 1 oz (28.5 g) tube

  • SPL UNCLASSIFIED SECTION

    Product identification code: 79043-150-28

    Image

    Consult instructions for use

    Image

    Use by date

    Image

    Batch code

    Image

    Sterilized using irradiation

    Image

    Do not use if the tube is damaged

    Image

    Upper limit of temperature
  • SPL UNCLASSIFIED SECTION

    Stratpharma AG
    Aeschenvorstadt 57
    CH-4051 Basel
    Switzerland

    Distributed by
    Allegis Pharmaceuticals
    Canton, MS 39046, USA

    Date of preparation of this
    information: 10/2020

    Stratpharma
    Switzerland

    scite
    PHARMA

    Questions:
    1-866-633-9033

    CE

    DP000USENPI01-1020

  • PRINCIPAL DISPLAY PANEL - 28.5 g Tube Box

    79043-150-28

    Rx Only
    For topical use only

    ADVANCED FORMULATION
    Derpixa
    for cutaneous reactions

    gel
    1 oz
    28.5 g

    PRINCIPAL DISPLAY PANEL - 28.5 g Tube Box
  • INGREDIENTS AND APPEARANCE
    DERPIXA 
    dressing, wound, occlusive
    Product Information
    Product TypeMEDICAL DEVICEItem Code (Source)NHRIC:79043-150
    Inactive Ingredients
    Ingredient NameStrength
    DIMETHICONE (UNII: 92RU3N3Y1O)  
    DIMETHICONOL (2000 CST) (UNII: T74O12AN6Y)  
    DIDECYLDIMONIUM CHLORIDE (UNII: JXN40O9Y9B)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NHRIC:79043-150-281 in 1 BOX
    128.5 g in 1 TUBE; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    Exempt deviceNAD12/15/2020
    Labeler - Scite Pharma, LLC (117555106)

  • Trademark Results [Derpixa]

    Mark Image

    Registration | Serial
    Company
    Trademark
    Application Date
    DERPIXA
    DERPIXA
    90322356 not registered Live/Pending
    Velocity Consulting Specialist, LLC
    2020-11-16

    © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.